Sutro Biopharma, Inc. (STRO) Tops Q2 EPS by 27c

Sutro Biopharma, Inc. (NASDAQ: STRO) reported Q2 EPS of ($0.14), $0.27 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $63.74 million versus the consensus estimate of $15.79 million.

For earnings history and earnings-related data on Sutro Biopharma, Inc. (STRO) click here.

You May Also Be Interested In

• SpaceX signs compute deal with Reflection - CNBC
• Rockwell Automation launches FactoryTalk Orchestration software
• Western Digital (WDC) call put ratio 1.2 calls to 1 put a focus on July 810 calls into Micron (MU) quarter results